Targeting the CD24-Siglec10 Axis: A Potential Strategy for Cancer Immunotherapy
Announcing a new article publication for BIO Integration journal. CD24, also known as heat-stable protein, is a highly glycosylated glycosylphosphatidylinositol junction membrane protein. CD24 specifically binds sialic-acid-binding Ig-like lectin 10 (Siglec10) on macrophages and serves as a “don’t eat me” signal, thus blocking the phagocytosis of tumor cells by macrophages and triggering tumor immune escape. Blocking the CD24-Siglec10 axis to reprogram the tumor immune microenvironment is a current research hotspot in cancer immunotherapy. Targeting the CD24-Siglec10 axis has received widespread attention, because of the high expression of CD24 on a variety of tumor cells and absence of blood toxicity. Targeting the CD24-Siglec10 axis as a cancer immunotherapy has shown favorable results and progress in preclinical studies. In this review, we summarize the discovery and functions of the CD24-Siglec10 axis, and review the roles and effects of this axis as a novel immune checkpoint in cancer immunotherapy. We also highlight recent advances in nanoparticle-mediated treatments targeting the CD24-Siglec10 axis for enhancing cancer immunotherapy.
https://www.scienceopen.com/hosted-document?doi=10.15212/bioi-2023-0022
BIO Integration is fully open access journal which will allow for the rapid dissemination of multidisciplinary views driving the progress of modern medicine.
As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience, BIOI will actively support authors through open access publishing and through waiving author fees in its first years. Also, publication support for authors whose first language is not English will be offered in areas such as manuscript development, English language editing and artwork assistance.
BIOI is now open for submissions; articles can be submitted online at:
https://mc04.manuscriptcentral.com/bioi
Please visit www.bio-integration.org to learn more about the journal.
Editorial Board: https://bio-integration.org/editorial-board/
Please visit www.bio-integration.org to learn more about the journal.
Editorial Board: https://bio-integration.org/editorial-board/
BIOI is available on the IngentaConnect platform (https://www.ingentaconnect.com/content/cscript/bioi) and at the BIO Integration website (www.bio-integration.org).
Submissions may be made using ScholarOne (https://mc04.manuscriptcentral.com/bioi).
There are no author submission or article processing fees.
Follow BIOI on Twitter @JournalBio; Facebook (https://www.facebook.com/BIO-Integration-Journal-108140854107716/) and LinkedIn (https://www.linkedin.com/company/bio-integration-journal/).
ISSN 2712-0074
eISSN 2712-0082
Junyue Fang, Li Lin and Yuan Cao et al. Targeting the CD24-Siglec10 Axis: A Potential Strategy for Cancer Immunotherapy. BIOI. 2024. Vol. 5(1). DOI: 10.15212/bioi-2023-0022
